GB Sciences (GBLX) 10-Q 18 Nov 15 2016 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Sep. 30, 2015	Nov. 17, 2015
Document and Entity Information:
Entity Registrant Name	Growblox Sciences, Inc.
Entity Central Index Key	1,165,320
Document Type	10-Q
Trading Symbol	GBLX
Document Period End Date	Sep. 30, 2015
Amendment Flag	false
Current Fiscal Year End Date	--03-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		46,750,647
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	Q2

CONSOLIDATED CONDENSED BALANCE

CONSOLIDATED CONDENSED BALANCE SHEETS (unaudited) - USD ($)	Sep. 30, 2015	Mar. 31, 2015
CURRENT ASSETS:
Cash and cash equivalents	$ 345,044
Accounts receivable, net	10,000	$ 50,000
Prepaid expenses	73,937	190,374
TOTAL CURRENT ASSETS	428,981	240,374
Property and Equipment, Net	1,587,364	913,642
Intangible Assets	3,555	3,555
Deposits and Prepayments	264,406	293,920
TOTAL ASSETS	2,284,306	1,451,491
CURRENT LIABILITIES:
Accounts Payable	1,096,447	677,230
Accrued Interest	10,572	230
Accrued Liabilities	145,062	72,776
Notes Payable	$ 1,588,858	180,000
Deferred Revenue		54,409
Deferred Compensation		1,522,537
TOTAL CURRENT LIABILITIES	$ 2,840,939	2,507,182
Deferred Revenue		220,506
Other Liabilities		654,968
TOTAL LIABILITIES	$ 2,840,939	$ 875,474
Commitments and Contingencies (Note 6)
STOCKHOLDERS' (DEFICIT)/EQUITY:
Common Stock, $0.0001 par value, 250,000,000 shares authorized, 46,310,814 and 35,972,929 shares issued and outstanding at September 30, 2015 and March 31, 2015	$ 4,631	$ 3,597
Deferred Stock Compensation	4,102,752	1,573,033
Additional Paid In Capital	13,522,374	10,751,690
Accumulated Deficit	(18,031,270)	(14,008,525)
TOTAL GROWBLOX SCIENCES, INC. STOCKHOLDERS' (DEFICIT)/EQUITY	(401,513)	(1,680,205)
Non-controlling interest	(155,120)	(250,960)
TOTAL (DEFICIT)/EQUITY	(556,633)	(1,931,165)
TOTAL LIABILITIES AND STOCKHOLDERS' (DEFICIT)/EQUITY	$ 2,284,306	$ 1,451,491

CONSOLIDATED CONDENSED BALANCE3

CONSOLIDATED CONDENSED BALANCE SHEETS (unaudited) (Parenthetical) - $ / shares	Sep. 30, 2015	Mar. 31, 2015
Statement of Financial Position [Abstract]
Common stock par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock authorized	250,000,000	250,000,000
Common Stock issued	46,310,814	35,972,929
Common Stock outstanding	46,310,814	35,972,929

STATEMENTS OF OPERATIONS (unaud

STATEMENTS OF OPERATIONS (unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Income Statement [Abstract]
NET REVENUE
GENERAL AND ADMINISTRATIVE EXPENSES	$ 2,693,145	$ 1,780,161	$ 4,215,910	$ 3,275,358
LOSS FROM OPERATIONS	$ (2,693,145)	(1,780,161)	(4,215,910)	(3,275,358)
OTHER INCOME (EXPENSE)
Interest Income		$ 160	1,218	$ 334
Interest Expense	$ (10,571)		(11,229)
Other	(985)		(985)
Total other expense	(11,556)	$ 160	(10,996)	$ 334
NET LOSS	(2,704,701)	(1,780,001)	(4,226,906)	(3,275,024)
Net income/(loss) attributable to non-controlling interest	(23,704)	(109,902)	(204,160)	(159,707)
NET LOSS ATTRIBUTABLE TO GROWBLOX SCIENCES, INC.	$ (2,680,997)	$ (1,670,099)	$ (4,022,746)	$ (3,115,317)
Net loss per share - basic and diluted (in dollars per share)	$ (0.06)	$ (0.07)	$ (0.09)	$ (0.12)
Weighted average common shares outstanding - basic and diluted (in shares)	46,104,790	34,046,111	43,331,875	25,515,847

STATEMENTS OF CASH FLOW (unaudi

STATEMENTS OF CASH FLOW (unaudited) - USD ($)	6 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
OPERATING ACTIVITIES:
Net income (loss)	$ (4,226,906)	$ (3,275,024)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	88,072	1,468
Stock-based compensation	1,751,264	$ 1,033,258
Deferred Compensation	(5,998)
Changes in operating assets and liabilities:
Accounts receivable	40,000
Prepaid expenses	116,437	$ (152,490)
Accounts payable	586,770	$ (314)
Accrued expenses	84,627
Net cash used in operating activities	(1,565,734)	$ (2,393,102)
INVESTING ACTIVITIES:
Purchase of property and equipment	(761,793)	(97,865)
Change in deposits	29,514	(77,483)
Net cash used in investing activities	(732,279)	(175,348)
FINANCING ACTIVITIES:
Net proceeds from the issuance of common stock and warrants	1,229,057	3,579,612
Proceeds from non-controlling interest	300,000	$ 112,500
Proceeds from notes payable	1,200,000
Repayment of debt	(30,000)
Cash used to purchase warrants	$ (56,000)
Other financing activities		$ 150,000
Stock subscription payable		25,250
Net cash provided by financing activities	$ 2,643,057	3,867,362
Net change in cash and cash equivalent	$ 345,044	1,298,912
CASH AND CASH EQUIVALENT AT BEGINNING OF PERIOD		339,327
CASH AND CASH EQUIVALENT AT END OF PERIOD	$ 345,044	1,638,239
Non-cash transactions:
Stock issued to satisfy debt	$ 167,451	1,262,411
Stock issued to settle interest expense		$ 252,304

Basis of Presentation and Signi

Basis of Presentation and Significant Accounting Policies	6 Months Ended
	Sep. 30, 2015
Accounting Policies [Abstract]
Basis of Presentation and Significant Accounting Policies	Note 1 – Basis of Presentation and Significant Accounting Policies Basis of Presentation The accompanying unaudited interim condensed consolidated financial statements of Growblox Sciences, Inc. (the “Company,” “We” or “Us”) have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulations S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the periods presented are not necessarily indicative of the results that may be expected for the year ending March 31, 2016. The balance sheet at March 31, 2015 has been derived from the audited financial statements at that date but does not include all of the information and footnotes required by U.S. GAAP for complete financial statements. For further information, refer to the consolidated financial statements and footnotes thereto included in the Company’s annual report on Form 10-K for the year ended March 31, 2015. Principles of Consolidation The consolidated financial statements include all operating divisions and majority owned subsidiaries, reported as a single operating segment, for which we maintain controlling interests. Intercompany accounts and transactions have been eliminated in consolidation. Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Reclassifications Certain reclassifications have been made to the comparative period amounts in order to conform to the current period presentation. These reclassifications had no effect on the reported financial position, results of operations or cash flows of the entity. Significant Accounting Policies A description of the Company’s significant accounting policies is included in Item 15 of its Annual Report on Form 10–K/A (Amendment No. 1) for the fiscal year ended March 31, 2015. Recent Accounting Pronouncements Management does not believe that any recently issued but not yet effective accounting pronouncements, if adopted, would have a material effect on the accompanying consolidated financial statements.

Going Concern

Going Concern	6 Months Ended
	Sep. 30, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Going Concern	Note 2 – Going Concern The Company’s financial statements have been prepared assuming the Company will continue as a going concern. The Company has sustained net losses since April 4, 2001, which have caused an accumulated deficit of approximately $18 million at September 30, 2015. In addition, the Company has consumed cash in its operating activities of approximately $1.6 million for the six months ended September 30, 2015 compared to $2.4 million for the same period last year. These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern. Management has been able, thus far, to finance the losses through a public offering, private placements and obtaining operating funds from stockholders. The Company is continuing to seek sources of financing. There are no assurances that the Company will be successful in achieving its goals. In view of these conditions, the Company’s ability to continue as a going concern is dependent upon its ability to obtain additional financing or capital sources, to meet its financing requirements, and ultimately to achieve profitable operations. Management believes that its current and future plans provide an opportunity to continue as a going concern. The accompanying financial statements do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classification of liabilities that may be necessary in the event the Company is unable to continue as a going concern.

License Fee

License Fee	6 Months Ended
	Sep. 30, 2015
Research and Development [Abstract]
License Fee	Note 3 – License Fee On December 16, 2014, the Company entered into an agreement to license certain proprietary equipment to an entity that intends to market the service of isolating particular cannabis strains for the purpose of developing tissue from those strains so as to create a consistent, brandable product of the customer’s choosing from any such strain. The agreement was conditional upon approval from the appropriate regulatory body. During the quarter ended September 30, 2015, the approval was not granted. The Company is obligated to return the fee amount received. Thus, the $0.3 million initial license fee received from licensor was reclassified to notes payable.

Note Payable

Note Payable	6 Months Ended
	Sep. 30, 2015
Debt Disclosure [Abstract]
Note Payable	Note 4 – Note Payable We entered into a Note Purchase Agreement, dated May 12, 2015 and effective as of June 8, 2015, with Pacific Leaf Ventures, LP (“Pacific Leaf”), pursuant to which Pacific Leaf has made installment loans (the “Loans”) to us in the aggregate amount of $1.5 million and is required to make $250,000 in additional Loans. To evidence the Loans, we issued to Pacific Leaf a 6% senior secured convertible promissory note (the “Note”), bearing interest at the rate of 6% per annum, payable quarterly. All outstanding principal and interest due under the Note is due and payable on May 12, 2020. We are required to prepay the outstanding principal amount of the Note on a quarterly basis in an amount equal to 50% of the cash flow (accrued EBITDA) of GBS Nevada attributable to our percentage interest in GBS Nevada no later than the earlier to occur of (a) the fifth (5th) business day following receipt of a distribution of the Company’s Share of GBS Nevada EBITDA for the calendar quarter in question, or (b) thirty (30) days following the end of the calendar quarter in question, with the first such prepayment to be made not later than July 31, 2015 with respect to the quarter ending June 30, 2015. In order to induce the Pacific Leaf to extend the loan to the Company, the Grantors have agreed to grant Secured Party security and assurance in order to secure the payment and performance of all of the Secured Obligations, and to that effect to grant Secured Party a security interest in certain of their assets and enter into the lending agreement. The purpose of the financing is to provide for the acquisition and installation of an operating facility, equipment and other tangible assets by GBS Nevada. Such facility and equipment will be dedicated to the cultivation of cannabis and the extraction of oils and other constituents present in cannabis, subject at all times to Nevada legal requirements. The note is convertible at the option of the holder into common shares at a conversion price of $0.50, subject to anti-dilution adjustments. As of September 30, 2015, the total amount of installments received is $1.2 million.

Capital Transactions

Capital Transactions	6 Months Ended
	Sep. 30, 2015
Stockholders' Equity Note [Abstract]
Capital Transactions	Note 5 – Capital Transactions During the six months ended September 30, 2015, the Board of Directors passed a resolution to temporarily reduce the exercise price of such B warrants from $2.00 per share to $0.20 per share in order to encourage the exercise of its B warrants, and the holders of the B warrants were notified of such temporary exercise price reduction. As a result of this incentive, B warrants to purchase 2,160,112 shares of common stock were exercised at $0.20 per share, resulting in net proceeds of $0.4 million. On April 22, 2015, the Chief Executive Officer of Growblox Sciences Puerto Rico LLC, purchased 2,820,000 shares of common stock for $0.6 million or $0.21 per share. The Company agreed to register such common stock for resale under the Securities Act pursuant to a registration rights agreement. In addition, the Company sold 1,995,833 shares of common stock to investors for $0.21 per share, resulting in total proceeds of $0.4 million. The Company issued 476,190 shares of common stock during the current period, the warrants of which were purchased in March 2015 for $0.21 per share, or $100,000. Between February, 2015 and May 15, 2015, certain holders of B Warrants sold back to the Company for $0.01 each, B warrants to purchase an aggregate of 1,600,000 shares of common stock. On April 27, 2015, two limited partnerships sold back to the Company for $0.01 each, warrants to purchase a total of 4,000,000 warrants for a total of $56,000. In May 2015, the Company issued 1,000,000 shares of common stock in connection with a cashless exercise of B warrants. During the six months ended September 30, 2015, the Company issued an aggregate of 2,252,000 shares of common stock in settlement and release of certain obligations owed by the Company to various persons and recorded related expenses of $1.7 million, as follows: The Company issued 150,000 and 95,250 shares of restricted common stock in connection with the conversions of $30,000 and $19,025 in indebtedness owed by us at a conversion price of $0.20 per share. The Company issued 796,000 shares of restricted common stock as compensation for consulting services. The Company recorded approximately $295,000 of compensation or $0.37 per share. The Company issued 19,500 shares of restricted common stock pursuant to the terms of a July 23, 2015 Investor Relations Consulting Agreement (the “IRCA”). The IRCA has a term of 12 months under which the Company is obligated to pay 6,500 shares per month to the consultant. The 19,500 shares represent payment for the first three months of the IRCA. The Company issued 424,400 shares of common stock to certain persons and employees and recorded an expense of $0.1 million. During the current period, the Company cancelled 892,400 shares of common stock of which 392,400 of the cancelled shares represented shares erroneously issued associated with unexercised options, 100,000 shares erroneously issued under an employment agreement, and 400,000 shares issued under an employment agreement which were subject to forfeiture. During the three months ended September 30, 2015, the Company modified and restructured certain employee agreements which resulted in a reclassification of previously recognized compensation obligations previously recorded as current and noncurrent obligations to equity. A portion of the related expense was recognized in the prior periods. Subsequent to September 30, 2015, the Company issued 333,333 shares of restricted common stock for aggregate consideration of $100,000, or $0.30 per share.

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Sep. 30, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 6 – Commitments and Contingencies On April 2, 2014, the Company commenced an action in the United States District Court for the Southern District of New York captioned Signature Exploration and Production Corporation v. GCM Administrative Services, LLC, Strategic Turnaround Equity Partners, L.P. (Cayman), Seth M. Lukash, and Gary Herman, 14 Civ. 02280 (ER) (the “Action”). After the change of name of Signature Exploration and Production Corporation, the caption was amended to substitute Growblox Sciences, Inc. as the plaintiff. The complaint in the Action sought a declaratory judgment that neither Lukash nor Herman was entitled to receive any interest in, including any shares of stock of, Growblox Sciences, Inc. pursuant to certain share conversion rights held under promissory notes in the aggregate amount of $75,000, given by a related party of ours to the entity defendants GCM and Strategic. On May 9, 2014, defendants filed an answer denying the complaint’s material allegations, and asserted a counterclaim against us, against persons identified as certain of our officers or directors, and against GrowOpp, LLC and Tumbleweed Holdings, Inc. On November 19, 2014, defendants filed an amended counterclaim, including a prayer for monetary relief or damages in the sum of $9 million. The Company moved to dismiss the counterclaim and by opinion dated June 2, 2015, the Court granted the motion in part and dismissed counts one and two (for declaratory judgment as to an alleged partnership or joint venture, and for breach of fiduciary duty predicated upon those allegations), and denied the motion in part, leaving counts three and four of the counterclaim standing. The Court viewed the third and fourth claims as a single claim for unjust enrichment, in which recovery would be based on quantum merit, that is, upon the alleged value of any benefit conferred by defendants to us through alleged work and services rendered. In view of the fact that the pleading did not assign a particular value to that claim we are unable at present to advise what specific sum of money damages is sought. The Company did not challenge the fifth count of the counterclaim at this stage that seeks damages of $75,000 for alleged non-payment of the above-referenced promissory notes. On August 19, 2015, Cathryn Kennedy, our former Chief Financial Officer, filed a Complaint against us in the District Court in Clark County, Nevada alleging that she was assigned new duties by us which constituted a termination without cause effective July 24, 2015, and that as a consequence thereof she is entitled to severance, vacation pay and stock compensation from us pursuant to her Employment Agreement dated November 18, 2014. The Company intends to vigorously defend itself against these allegations. From time to time, the Company also becomes involved in certain legal proceedings and claims which arise in the ordinary course of business. In our opinion, based on consultations with outside counsel, the results of any of these ordinary course matters, individually and in the aggregate, are not expected to have a material effect on our results of operations, financial condition, or cash flows. As more information becomes available, if management should determine that an unfavorable outcome is probable on such a claim and that the amount of such probable loss that it will incur on that claim is reasonably estimable, we will record a reserve for the claim in question. If and when we record such a reserve is recorded, it could be material and could adversely impact our results of operations, financial condition, and cash flows.

Loss per Share

Loss per Share	6 Months Ended
	Sep. 30, 2015
Earnings Per Share [Abstract]
Loss per Share	Note 7 – Loss per Share The Company’s basic loss per share has been calculated using the weighted average number of common shares outstanding during the period. The Company had 46,104,790 and 29,520,288 potentially dilutive common shares at September 30, 2015 and March 31, 2015, respectively. However, such common stock equivalents were not included in the computation of diluted net loss per share as their inclusion would have been anti-dilutive.

Basis of Presentation and Sig13

Basis of Presentation and Significant Accounting Policies (Policies)	6 Months Ended
	Sep. 30, 2015
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying unaudited interim condensed consolidated financial statements of Growblox Sciences, Inc. (the “Company,” “We” or “Us”) have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulations S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the periods presented are not necessarily indicative of the results that may be expected for the year ending March 31, 2016. The balance sheet at March 31, 2015 has been derived from the audited financial statements at that date but does not include all of the information and footnotes required by U.S. GAAP for complete financial statements. For further information, refer to the consolidated financial statements and footnotes thereto included in the Company’s annual report on Form 10-K for the year ended March 31, 2015.
Principles of Consolidation	Principles of Consolidation The consolidated financial statements include all operating divisions and majority owned subsidiaries, reported as a single operating segment, for which we maintain controlling interests. Intercompany accounts and transactions have been eliminated in consolidation.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Reclassifications	Reclassifications Certain reclassifications have been made to the comparative period amounts in order to conform to the current period presentation. These reclassifications had no effect on the reported financial position, results of operations or cash flows of the entity.
Significant Accounting Policies	Significant Accounting Policies A description of the Company’s significant accounting policies is included in Item 15 of its Annual Report on Form 10–K/A (Amendment No. 1) for the fiscal year ended March 31, 2015.
Recently Adopted Accounting Pronouncements	Recent Accounting Pronouncements Management does not believe that any recently issued but not yet effective accounting pronouncements, if adopted, would have a material effect on the accompanying consolidated financial statements.

Going Concern (Details Narrativ

Going Concern (Details Narrative) - USD ($)	6 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Mar. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accumulated deficit	$ (18,031,270)		$ (14,008,525)
Net cash used in operating activities	$ (1,565,734)	$ (2,393,102)

License Fee (Details Narrative)

License Fee (Details Narrative)	3 Months Ended
	Sep. 30, 2015USD ($)
Research and Development [Abstract]
License fee	$ 300,000

Note Payable (Details Narrative

Note Payable (Details Narrative) - USD ($)	May. 12, 2015	Sep. 30, 2015	Mar. 31, 2015
Notes payable		$ 1,588,858	$ 180,000
Note Purchase Agreement (Pacific Leaf Ventures, LP) [Member]
Interest rate	6.00%
Additional borrowings	$ 250,000
Maximum loan amount	$ 1,500,000
Conversion price (in dollars per share)	$ 0.50
Notes payable	$ 1,200,000

Capital Transactions (Details N

Capital Transactions (Details Narrative) - USD ($)	Apr. 27, 2015	Apr. 22, 2015	May. 30, 2015	Sep. 30, 2015	Sep. 30, 2015	May. 15, 2015
Number of common shares issued upon conversion					2,252,000
Value of common shares issued upon conversion					$ 1,700,000
Number of shares issued for consulting services					796,000
Value of shares issued for consulting services					$ 295,000
Total number of shares cancelled					892,400
Number of shares cancelled for unexercised options					392,400
Number of shares cancelled for employment agreement					100,000
Number of shares cancelled for forfeitured employment agreement					400,000
Share price for consulting services (in dollars per shares)				$ 0.37	$ 0.37
Investor Relations Consulting Agreement [Member]
Agreement term					12 months
Restricted Common Stock [Member] | Subsequent Event [Member]
Number of common shares issued					333,333
Value of common shares issued					$ 100,000
Share price (in dollars per shares)				0.30	$ 0.30
Restricted Common Stock [Member] | Investor Relations Consulting Agreement [Member]
Number of common shares issued					19,500
Convertible Debt [Member] | Restricted Common Stock [Member]
Number of common shares issued upon conversion					150,000
Value of common shares issued upon conversion					$ 30,000
Conversion price (in dollars per shares)				0.20	$ 0.20
Description of types of equity issued upon conversion					Restricted common stock.
Convertible Debt [Member] | Restricted Common Stock [Member]
Number of common shares issued upon conversion					95,250
Value of common shares issued upon conversion					$ 19,025
Conversion price (in dollars per shares)				0.20	$ 0.20
Description of types of equity issued upon conversion					Restricted common stock.
Investor [Member]
Number of common shares issued		1,995,833
Value of common shares issued		$ 400,000
Share price (in dollars per shares)		$ 0.21
Growblox Sciences Puerto Rico LLC [Member] | Chief Executive Officer [Member]
Number of common shares issued		2,820,000
Value of common shares issued		$ 600,000
Share price (in dollars per shares)		$ 0.21
Certain Persons and Employees [Member]
Number of common shares issued					424,400
Value of common shares issued					$ 100,000
B Warrants [Member]
Exercise price (in dollars per shares)				2	$ 2
Temporarily revised exercise price (in dollars per shares)				$ 0.20	$ 0.20	$ 0.01
Number of common shares issued			1,000,000	2,160,112
Value of common shares issued				$ 400,000
Number of common shares called						1,600,000
Warrants [Member]
Number of common shares issued		476,190
Value of common shares issued		$ 100,000
Share price (in dollars per shares)		$ 0.21
Warrants [Member] | Two Limited Partnerships [Member]
Temporarily revised exercise price (in dollars per shares)	$ 0.01
Number of common shares called	4,000,000
Value of common shares called	$ 56,000

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative) - GCM and Strategic [Member] - USD ($)	Nov. 19, 2014	Sep. 30, 2015
Loss contingency, damages sought, value		$ 75,000
Monetary relief or damages	$ 9,000,000

Loss per Share (Details Narrati

Loss per Share (Details Narrative) - shares	6 Months Ended	12 Months Ended
	Sep. 30, 2015	Mar. 31, 2015
Common stock [Member]
Potentially dilutive shares	46,104,790	29,520,288